AAVogen, Inc.
PrivateLast Round
Grant
Sep 5, 2025
Total Funding Raised
$4.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AAVogen, Inc. operates in Healthcare & Life Sciences and is based in Rockville, Maryland. Its latest recorded funding round was a Grant round in September 2025.
AAVogen, Inc. is a biotechnology company that develops gene therapeutics for muscle wasting diseases such as inclusion body myositis, Duchenne muscular dystrophy, and heart failure.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AAVogen, Inc. Comparables
Compare AAVogen, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MyoGene Bio | 84% | |
| Myosana Therapeutics | 83% | |
| Orphina Biotechnology | 82% |
For institutional investors. Book with your work email.
AAVogen, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 5, 2025 | ||||
| Grant | Jun 10, 2023 | ||||
| Grant | Sep 1, 2022 | ||||
| Grant | Sep 1, 2019 | ||||
| Grant | Sep 1, 2017 | ||||
Grant | Dec 3, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AAVogen, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | Grant |
| Washington State University | Grant |
| National Institute on Aging | Grant |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Washington Research Foundation Capital | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 105% MoM.
- May 15, 2026
Monthly visitors grew 264% MoM, reaching 1.1K.
For institutional investors. Book with your work email.
AAVogen, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AAVogen, Inc.'s valuation, stock price, and market status.
Is AAVogen, Inc. a public or private company?
AAVogen, Inc. is a private company.
What is the current stock price of AAVogen, Inc.?
AAVogen, Inc. is a private company, so its shares have no public market price. Caplight tracks AAVogen, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AAVogen, Inc. worth (valuation)?
Valuation information for AAVogen, Inc. is not publicly available.
Can I buy AAVogen, Inc. stock?
AAVogen, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AAVogen, Inc.'s last funding round?
AAVogen, Inc.'s most recent funding round was Grant on September 5, 2025.
Who are the main investors in AAVogen, Inc.?
Key investors in AAVogen, Inc. include National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Washington State University, National Institute on Aging, National Institute of Diabetes and Digestive and Kidney Diseases.
Will AAVogen, Inc. IPO soon?
No public IPO plans have been announced for AAVogen, Inc..
How can I track AAVogen, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in AAVogen, Inc.'s shares on secondary markets.